Clinical Trials
TG4010 vaccine plus nivolumab shows limited activity in NSCLC trial
Wang et alOncoimmunology

A multi-institutional single-arm phase II trial (NCT02823990) evaluated the safety and therapeutic activity of the mucin 1 (MUC1) targeted vaccine TG4010 combined with nivolumab in immune checkpoint inhibitor (ICI)-naïve patients with non-small cell lung cancer (NSCLC). Designed with a target accrual of 29 evaluable patients and a primary efficacy threshold of at least 10 responders, the trial was terminated early due to slow accrual after enrolling 13 patients. Among the 12 evaluable patients, the combination yielded limited clinical benefit, with an overall response rate of 8.3% (1/12), disease control in 2 patients, disease progression in 9 patients, and a median overall survival of 7.23 months.\n\nSafety assessments indicated the regimen was well tolerated, with the most frequent adverse events being fatigue (grades 1–3) and injection site reactions (grades 1–2). Biomarker analyses demonstrated that therapy decreased tumor MUC1 expression and T-cell PD-1 levels while upregulating innate and adaptive immune response pathways in tumors and circulating immune cells. However, TCR sequencing showed no evidence of T-cell clonal expansion or epitope spreading, accounting for the insufficient overall efficacy. Notably, one patient with a HER2 driver mutation achieved an ongoing durable complete response, which correlated with marked baseline upregulation of gene set enrichment analysis (GSEA) pathways involved in interferon signaling.
Key Takeaways
- Combination therapy with TG4010 and nivolumab demonstrated limited clinical activity in immune checkpoint inhibitor (ICI)-naïve non-small cell lung cancer, yielding a response rate of 8.3% (1/12 evaluable patients) and a median overall survival of 7.23 months.
- Treatment was well tolerated with fatigue (grades 1–3) and injection site reactions (grades 1–2) as the primary adverse events, though TCR sequencing revealed no T-cell clonal expansion or epitope spreading.
- An exceptional ongoing durable complete response was observed in a patient harboring a HER2 driver mutation who displayed significant baseline upregulation of interferon-signaling pathways.
Read the original sourceOncoimmunology
